Somatostatin

CAS 38916-34-6 6 current records 4 historicalProtein

Who holds supplier records for Somatostatin? 6 organisations hold a current record for Somatostatin: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 5 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Spain (1), China (1), India (1) and Sweden (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Somatostatin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/somatostatin

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 4 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Somatostatin. Country is the organisation's recorded country, not necessarily the manufacturing site.

Spain1China1India1Sweden1Country not recorded for 2
  • HARBIN JIXIANGLONG BIOTECH CO LTD
    Active DMF 39985 · latest filing May 2024
  • BACHEM AG
    CEP Company GMP cert on record
  • SpainCEP
  • Hybio Pharmaceutical Co., Ltd.
    ChinaCEP Company GMP cert on record
  • IndiaCEP Company GMP cert on record
  • PolyPeptide Laboratories (Sweden) AB
    SwedenCEP Company GMP cert on record
Need Somatostatin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (5)

Certificates of Suitability on the EDQM register for Somatostatin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 8 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HYBIO PHARMACEUTICAL CO., LTD. ShenzhenCN
CEP 2024-027 - Rev 00
Somatostatin
Aug 2024—
PIRAMAL PHARMA LIMITED MumbaiIN
R1-CEP 2011-008 - Rev 02
Somatostatin
Oct 2022—
PolyPeptide Laboratories (Sweden) AB LimhamnSE
R1-CEP 2010-169 - Rev 03
Somatostatin, F
Sept 2022—
Bachem AG BubendorfCH
R1-CEP 2005-245 - Rev 02
Somatostatin
Jul 2021—
BCN PEPTIDES S.A. St Quinti De MedionaES
R1-CEP 1999-035 - Rev 03
Somatostatin
Nov 2008—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (4)

Organisations whose Type II DMFs for Somatostatin are no longer active. These show a past filing, not current supply.

Show all 4 historical records
  • SIGMA F AND D DIV LTD
    Inactive DMF 10188 · filed Apr 1993
  • DIAMALT AG
    Inactive DMF 5481 · filed Jul 1984
  • CENTRE DE RECHERCHES CLINIC MIDY
    Inactive DMF 3944 · filed Jul 1980
  • BECKMAN INSTRUMENTS INC DIV SMITHKLINE BECKMAN CORP
    Inactive DMF 3431 · filed Dec 1978

Overview

Somatostatin is a protein active pharmaceutical ingredient (ChEMBL CHEMBL1823872).

Chemical identity

IUPAC name
(4R,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
Canonical SMILES
C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
InChIKey
NHXLMOGPVYXJNR-ATOGVRKGSA-N
Synonyms
Somatostatin, Somatostatin-14, Somatostatina, Somatostatine, SRIF-14, Cyclic Somatostatin, Somatostatin 14, Somatostatinum, Somatostatin, cyclic, Synthetic somatostatin-14, Somatostatin-1, Panhibin

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Somatostatin?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Somatostatin: HARBIN JIXIANGLONG BIOTECH CO LTD, BACHEM AG, BCN PEPTIDES SA (Spain), Hybio Pharmaceutical Co., Ltd. (China), Piramal Pharma Limited (India) and PolyPeptide Laboratories (Sweden) AB (Sweden). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Somatostatin Drug Master Files are active?

HARBIN JIXIANGLONG BIOTECH CO LTD (DMF 39985). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Somatostatin records mean?

4 organisations have only inactive Type II DMFs for Somatostatin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Somatostatin have a European Certificate of Suitability?

Yes. 5 organisations hold a valid CEP for Somatostatin on the EDQM register, including HYBIO PHARMACEUTICAL CO., LTD. Shenzhen (CN), PIRAMAL PHARMA LIMITED Mumbai (IN), PolyPeptide Laboratories (Sweden) AB Limhamn (SE), Bachem AG Bubendorf (CH) and BCN PEPTIDES S.A. St Quinti De Mediona (ES). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Somatostatin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Somatostatin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.